$GHSI
Guardion Health Sciences Inc Stock $ghsi

$ghsi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016929 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$2.790M	$3.186M	$2.385M
YoY Change	-14.82%	33.59%	936.79%
Cost Of Revenue	$1.541M	$1.850M	$1.288M
YoY Change	-17.87%	43.65%	890.89%
Gross Profit	$1.249M	$1.335M	$1.096M
YoY Change	-10.74%	21.78%	996.46%
Gross Profit Margin	44.78%	41.92%	45.98%
Selling, General & Admin	$2.185M	$2.737M	$3.686M
YoY Change	-27.55%	-25.75%	34.02%
% of Gross Profit	174.88%	204.94%	336.13%
Research & Development	$77.20K	$62.73K	$6.690K
YoY Change	-19.18%	837.73%	-66.55%
% of Gross Profit	6.18%	4.7%	0.61%
Depreciation & Amortization	$4.830K	$4.790K	$317.1K
YoY Change	-75.39%	-98.49%	1485.25%
% of Gross Profit	0.39%	0.36%	28.92%
Operating Expenses	$2.262M	$2.799M	$3.692M
YoY Change	-27.3%	-24.18%	33.29%
Operating Profit	-$1.013M	-$1.464M	-$2.596M
YoY Change	-40.84%	-43.6%	-2.78%
Interest Expense	$95.54K	$1.997M	$1.560K
YoY Change	893.14%	127919.23%
% of Operating Profit
Other Income/Expense, Net	-$159.8K	$1.997M	-$2.681M
YoY Change	-1761.62%	-174.49%
Pretax Income	-$1.172M	$533.1K	-$2.618M
YoY Change	-31.11%	-120.36%	-1.93%
Income Tax
% Of Pretax Income
Net Earnings	-$1.172M	$533.1K	-$2.618M
YoY Change	-31.11%	-120.36%	-1.91%
Net Earnings / Revenue	-42.02%	16.73%	-109.81%
Basic Earnings Per Share	-$0.93	$0.42	-$7.00
Diluted Earnings Per Share	-$0.93	$0.42	-$66.88K
COMMON SHARES
Basic Shares Outstanding	1.267M shares	1.267M shares	783.0K shares
Diluted Shares Outstanding	1.267M shares	1.267M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.370M	$8.775M	$16.83M
YoY Change	-41.19%	-47.86%	-61.16%
Cash & Equivalents	$8.366M	$8.775M	$4.832M
Short-Term Investments			$12.00M
Other Short-Term Assets	$1.000M	$590.7K	$717.6K
YoY Change	-13.49%	-17.69%	131.49%
Inventory	$2.513M	$3.061M	$822.3K
Prepaid Expenses
Receivables	$1.555M	$1.947M	$2.198M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.43M	$14.37M	$20.57M
YoY Change	-29.68%	-30.12%	-53.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$43.04K	$45.73K	$94.23K
YoY Change	-42.3%	-51.47%	-85.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$43.04K	$45.73K	$11.05M
YoY Change	-99.6%	-99.59%	1478.94%
TOTAL ASSETS
Total Short-Term Assets	$13.43M	$14.37M	$20.57M
Total Long-Term Assets	$43.04K	$45.73K	$11.05M
Total Assets	$13.47M	$14.42M	$31.62M
YoY Change	-54.84%	-54.4%	-29.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$985.3K	$888.6K	$1.146M
YoY Change	-10.08%	-22.49%	398.42%
Accrued Expenses	$452.5K	$508.7K	$680.0K
YoY Change	-22.29%	-25.19%	0.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.997M	$2.178M	$1.826M
YoY Change	17.91%	19.25%	86.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.240M	$3.759M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$4.240M	$3.759M	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.997M	$2.178M	$1.826M
Total Long-Term Liabilities	$4.240M	$3.759M	$0.00
Total Liabilities	$6.233M	$5.937M	$1.826M
YoY Change	268.12%	225.07%	50.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$94.36M	-$93.19M	-$84.10M
YoY Change	13.52%	10.81%
Common Stock	$1.267K	$1.267K
YoY Change	-97.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.241M	$8.482M	$29.79M
YoY Change
Total Liabilities & Shareholders Equity	$13.47M	$14.42M	$31.62M
YoY Change	-54.84%	-54.4%	-29.26%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.172M	$533.1K	-$2.618M
YoY Change	-31.11%	-120.36%	-1.91%
Depreciation, Depletion And Amortization	$4.830K	$4.790K	$317.1K
YoY Change	-75.39%	-98.49%	1485.25%
Cash From Operating Activities	-$406.5K	-$1.879M	-$2.226M
YoY Change	-84.21%	-15.6%	-8.0%
INVESTING ACTIVITIES
Capital Expenditures	$2.140K	$1.654K	-$2.400K
YoY Change		-168.92%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$7.002M
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$2.140K	-$1.654K	-$7.004M
YoY Change	-100.11%	-99.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	-$5.250M	9.969M
YoY Change	-100.0%	-152.66%	-73.22%
NET CHANGE
Cash From Operating Activities	-406.5K	-$1.879M	-2.226M
Cash From Investing Activities	-2.140K	-$1.654K	-7.004M
Cash From Financing Activities	0.000	-$5.250M	9.969M
Net Change In Cash	-408.6K	-$7.131M	738.6K
YoY Change	-32.78%	-1065.52%
FREE CASH FLOW
Cash From Operating Activities	-$406.5K	-$1.879M	-$2.226M
Capital Expenditures	$2.140K	$1.654K	-$2.400K
Free Cash Flow	-$408.6K	-$1.881M	-$2.224M
YoY Change	-84.13%	-15.43%	-8.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001642375
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2023Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2023Q1	GHSI	Payments To Acquire Treasury Bills PaymentsToAcquireTreasuryBills		usd
CY2023Q1	GHSI	Proceeds From Sale Of Treasury Bills ProceedsFromSaleOfTreasuryBills		usd
CY2022Q1	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	GHSI	Issuance Of Warrant Liability IssuanceOfWarrantLiability		usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38861
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	GUARDION HEALTH SCIENCES, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4428421
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2925 Richmond Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1200
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77098
CY2023Q1	dei	City Area Code CityAreaCode	800
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	873-5141
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	GHSI
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1267340	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8774626	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10655490	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	5250000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1946746	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1924353	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	3060919	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3119421	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	590698	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	687933	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	14372989	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	21637197	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45733	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48871	usd
CY2023Q1	us-gaap	Assets Assets	14418722	usd
CY2022Q4	us-gaap	Assets Assets	21686068	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	888568	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1518052	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	508730	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	558287	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3807	usd
CY2023Q1	GHSI	Warrant Derivative Liability Current WarrantDerivativeLiabilityCurrent	780700	usd
CY2022Q4	GHSI	Warrant Derivative Liability Current WarrantDerivativeLiabilityCurrent	1931400	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2177998	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4011546	usd
CY2023Q1	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent	3759200	usd
CY2022Q4	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent	4506600	usd
CY2023Q1	us-gaap	Liabilities Liabilities	5937198	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8518146	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5250000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1267340	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1267340	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1267340	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1267340	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	1267	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1267	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101671466	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101640955	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93191209	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93724300	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8481524	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7917922	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14418722	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21686068	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3185689	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2384619	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1850387	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1288162	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1335302	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	1096457	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62734	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6691	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	598655	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	668645	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2137920	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3016912	usd
CY2022Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	24257	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2799309	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	3716505	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1464007	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2620048	usd
CY2023Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1898100	usd
CY2022Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-2682500	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	98998	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	1561	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1997098	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2680939	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	533091	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5300987	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.42
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.77
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1267340	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	783018	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7917922	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	25182	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	5329	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	533091	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8481524	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8481524	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22297800	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	85963	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	59906	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	8834898	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	8783800	usd
CY2022Q1	GHSI	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1134040	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5300987	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5300987	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	18327820	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	18327820	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	533091	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5300987	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4792	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	317050	usd
CY2022Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	24257	usd
CY2023Q1	GHSI	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	25182	usd
CY2022Q1	GHSI	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	85963	usd
CY2023Q1	GHSI	Fair Value Of Vested Restricted Common Stock FairValueOfVestedRestrictedCommonStock	5329	usd
CY2022Q1	GHSI	Fair Value Of Vested Restricted Common Stock FairValueOfVestedRestrictedCommonStock	59906	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1898100	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2682500	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	22393	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	786827	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-58501	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	454637	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-97235	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-482746	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-629483	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	905022	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3807	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5390	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-49557	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-236076	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1879210	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2226473	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1654	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2404	usd
CY2022Q1	GHSI	Payments To Acquire Treasury Bills PaymentsToAcquireTreasuryBills	21977077	usd
CY2022Q1	GHSI	Proceeds From Sale Of Treasury Bills ProceedsFromSaleOfTreasuryBills	14975557	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1654	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7003924	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	5250000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	8834899	usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1134040	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5250000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9968939	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7130864	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	738542	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15905490	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4093927	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8774626	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4832469	usd
CY2022Q1	GHSI	Issuance Of Warrant Liability IssuanceOfWarrantLiability	8783800	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1464007	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1879210	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8774626	usd
CY2023Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-fifty (1:50) 2023 Reverse Stock Split
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6438000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13294	shares
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zmeHl5aa2fDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zlJKp7wCBojd">Use of Estimates</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. Actual results could differ from those estimates. On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1996	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3185689	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2384619	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3185689	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2384619	usd
CY2023Q1	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	1937000	usd
CY2022Q1	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	1847000	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	479866	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	587361	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_ziY9zYvLql3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zMncFKPJzTVj">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue. </i>During the three months ended March 31, 2023, the Company had three customers that accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomerMember_zZG7kvYBdZ77" title="Concentration risk percentage 1">80</span>% of total revenue. The largest customer accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zJhbDxOeT8F5" title="Concentration risk percentage 1">59</span>% of the Company’s total revenue, the second largest customer accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondLargestCustomerMember_zb3turqDvMKf">11</span>% of the Company’s total revenue and the third largest customer accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThirdLargestCustomerMember_zPPnraEglA44">10</span>% of the Company’s revenue. During the three months ended March 31, 2022, the Company had one customer that accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zBov3nqyIcHg" title="Concentration risk percentage 1">59</span>% of the Company’s total revenue. No other customer accounted for more than <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zuvsRSv0GFUe"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zHblbXiF9kag">10</span></span>% of revenue during the three months ended March 31, 2023 and the three months ended March 31, 2022. The Company sells the majority of its products to one of the largest retailers in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Accounts receivable</i>. As of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023<span style="background-color: white">, the Company had accounts receivable from one customer which comprised approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zcj7QkStrfS3" title="Concentration Risk, Percentage">67</span>% of its accounts receivable. As of </span>December 31, 2022<span style="background-color: white">, the Company had accounts receivable from one customer which comprised approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zT0cIuKVu1c8" title="Concentration Risk, Percentage">88</span>% of its accounts receivable. No other customer accounted for more than <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zwvVfcU13Npj" title="Concentration Risk, Percentage"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zKxDqIF2htu" title="Concentration Risk, Percentage">10</span></span>% of accounts receivable as of </span>March 31, 2023 <span style="background-color: white">and December 31, 2022. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Purchases from vendors</i>. During the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">three months ended March 31, 2023<span style="background-color: white">, the Company utilized one manufacturer for most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneManufacturerMember_zTQWvjV1vtvl" title="Concentration Risk, Percentage">49</span>% of all purchases during the three months ended </span>March 31, 2023<span style="background-color: white">. The Company utilized a firm to manage and handle media and advertising of its clinical nutrition products. Total purchases from this vendor accounted for approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember_zcCGuO27Qltc">13</span>% of all purchases during the three months ended </span>March 31, 2023. During the three months ended March 31, 2022<span style="background-color: white">, the Company’s largest vendor accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--LargestVendorMember_zqPLNcjVtzfd" title="Concentration Risk, Percentage">41</span>% of all purchases. No other vendors accounted for more than <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zWxqmYgA9Ae5"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_z3kwN37Pm9Nl">10</span></span>% of purchases during the </span>three months ended March 31, 2023 <span style="background-color: white">and 2022.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Accounts payable</i>. As of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2023<span style="background-color: white">, two vendors accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoVendorsMember_zLTivlx9TLre" title="Concentration Risk, Percentage">80</span>% of total accounts payable. One vendor accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zqzBVbit8SH1" title="Concentration Risk, Percentage">70</span>% and a second vendor accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondVendorMember_z7eZLyGSyZXi" title="Concentration Risk, Percentage">10</span>% of the accounts payable at March 31, 2023. As of </span>December 31, 2022, <span style="background-color: white">one vendor accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zTiVTpd9kZI1" title="Concentration Risk, Percentage">88</span>% of the total accounts payable. No other vendor accounted for more than <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zPXBrhjPndTg" title="Concentration risk, percentage"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zg3hCOkw2YPg" title="Concentration risk, percentage">10</span></span>% of accounts payable as of </span>March 31, 2023 <span style="background-color: white">and December 31, 2022.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash and cash equivalents.</i> Cash and cash equivalents consist of funds deposited with BMO Harris Bank(“BMO”), a major, established, high quality financial institution and short-term (original maturity of generally 60 days or less) liquid investments in money market deposit accounts. Cash equivalents are classified as Level 1 in the GAAP valuation hierarchy and are valued using the net asset value (“NAV”) per share of the money market fund. The Company has an overnight investment feature established with BMO whereby the Company’s cash is swept into a Money Market Mutual Fund managed by Goldman Sachs Asset Management. This fund invests solely in high quality U.S. government issued securities. As of March 31, 2023, $<span id="xdx_907_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230331_zggfkXHl0HM9" title="Cash and cash equivalents balance">8,774,626</span> included in cash and cash equivalents was held in the Goldman Sachs Financial Square Government Institutional Fund, a fund that is not insured by the Federal Deposit Insurance Corporation (the “FDIC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_90B_eus-gaap--CashFDICInsuredAmount_iI_c20230331_zxq7YPuGTPqg" title="Cash FDIC insured amount">250,000</span> and $<span id="xdx_908_ecustom--CashSIPCInsuredAmount_iI_c20230331_z8qtSnRSBixg" title="Cash SIPC insured amount">500,000</span>, respectively. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because of its assessment of the creditworthiness and financial viability of the financial institutions that hold such cash balances. The Company has not experienced any losses to date resulting from this policy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8774626	usd
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q1	GHSI	Cash Sipc Insured Amount CashSIPCInsuredAmount	500000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1539827	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1544763	shares
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	4539900	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6438000	usd
CY2023Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1898100	usd
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	4539900	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	49652	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	49637	usd
CY2023Q1	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	3011267	usd
CY2022Q4	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	3069784	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	3060919	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3119421	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11900000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	10065833	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	297500	usd
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2700	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	24257	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	22221	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3807	usd
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	4539900	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6438000	usd
CY2022Q4	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	The Certificates of Designation for the Preferred Stock provided that the Preferred Stock had no voting rights other than the right to vote on the Amendment and as a class on certain other specified matters, and, with respect to the Series D Certificate of Designation, the right to cast 1,000,000 votes per share of Series D Preferred Stock on the Reverse Stock Split proposal. The Amendment required the approval of the majority of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. On January 5, 2023, the Amendment to authorize a reverse split of the Common Stock was approved at a special meeting of stockholders. Following the meeting, the board of directors approved a one-for-fifty (1-for-50) reverse split of the Company’s issued and outstanding shares of common stock
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4750000	usd
CY2022	GHSI	Proceeds From Issuance Of Private Placement Additional ProceedsFromIssuanceOfPrivatePlacementAdditional	500000	usd
CY2022	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1.05	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1526701	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	217.05
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	835	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	750.00
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12459	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	217.05
CY2023Q1	GHSI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y9M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10152	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	252.06
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12459	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10152	shares

Files In Submission

Name	View Source	Status
0001493152-23-016929-index-headers.html	Edgar Link	pending
0001493152-23-016929-index.html	Edgar Link	pending
0001493152-23-016929.txt	Edgar Link	pending
0001493152-23-016929-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
ghsi-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
ghsi-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ghsi-20230331_lab.xml	Edgar Link	unprocessable
ghsi-20230331_def.xml	Edgar Link	unprocessable
ghsi-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GHSI
Guardion Health Sciences Inc Stock $ghsi

2023 Q2 Form 10-Q Financial Statement

#000149315223016929 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GHSI Guardion Health Sciences Inc Stock $ghsi

2023 Q2 Form 10-Q Financial Statement

#000149315223016929 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GHSI
Guardion Health Sciences Inc Stock $ghsi